New Strategy Shifts Pfizer Away from New Hep C Drug
Pfizer Stops Developing Hepatitis C Drug, Cites Strategic Review
Published March 08, 2013 | Dow Jones Newswires
Pfizer Inc. (PFE) has stopped development of an experimental hepatitis C drug, bowing out of a hotly contested industry race to introduce the next generation of treatments for the infectious liver disease.
The New York-based drug giant decided to discontinue development of PF-00868554, also known as filibuvir, following a strategic review, said spokeswoman Victoria Davis. She said the decision wasn’t related to any safety issues.
Continue reading this entire article:
Hepatitis C and Body Piercing
BiolineRX Gains Momentum for Pre-Clinical HCV Drug